TrialAssure Releases ANONYMIZE DS
TrialAssure, a global software company focused on developing clinical trial transparency tools-announced the full release of ANONYMIZE DS, the new software-as-a-service (SaaS) application that utilizes automation to anonymize sponsor’s clinical trial data, during the DIA Global Clinical Trial Disclosure and Data Transparency Conference. Gathering user feedback since its limited release February 2019, TrialAssure ANONYMIZE DS is now fully available to the public.
“As one of the first groups to automate the anonymization of datasets, our developers heard first-hand feedback from industry users during the limited release of the product and fine-tuned ANONYMIZE DS to best meet their needs,” says Zach Weingarden, Product Solutions Manager, TrialAssure. “As with all software we develop, our development team is open to engaging end users, actively encouraging feedback and listening carefully to their suggestions.”
Key features of TrialAssure ANONYMIZE DS, include:
- Fits alongside other TrialAssure applications within the transparency suite of products, allowing for single dashboard reporting and synchronized workflows across all transparency related data and document deliverables
- Transforming original data into anonymized data, using industry-standard techniques that can be reused and customized for each dataset
- Assigning a risk score associated with the re-identification of this data based on thresholds set by the sponsor
- Configurability to sponsor specifications
- A user interface that allows for ease of transition from manual processes
- Use of modern machine learning technology to drive efficiency
“All pharmaceutical sponsors will need to rely on anonymization methods, and therefore tools, to stay ahead of transparency regulations, as redaction of data limits data utility,” says Mohamad Zahreddine, CIO, TrialAssure, and member of the Forbes Technology Council. “Transparency experts and thoughtful developers have banded together, utilizing the latest technology to build a software application that is of great importance to the future of the pharmaceutical industry, and more broadly, all those in clinical research. We want global teams to #BeTransparent, and it’s in everyone’s best interest that while we must first protect privacy, the data shared should be usable.”
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
